Glenn S. Boehnlein - 10 Sep 2026 Form 4 Insider Report for DEXCOM INC (DXCM)

Reporting relationship: Director
Issuer ticker: DXCM
Reported as of: 10 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Sep 2026, 16:40:16 UTC
Prior SEC filing: 10 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Jereme M. Sylvain, as Attorney-in-Fact for Glenn S. Boehnlein

Key filing fact

Glenn S. Boehnlein filed Form 4 for DEXCOM INC (DXCM) on 10 Sep 2026.

Key facts

This page summarizes Glenn S. Boehnlein's Form 4 filing for DEXCOM INC (DXCM).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 10 Sep 2026, 16:40.

Change

Previous filing in this sequence was filed on 10 Sep 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001670936 Primary reporting owner

Boehnlein Glenn S

Relationship: Director
Address: 6340 SEQUENCE DRIVE, SAN DIEGO
Signature: /s/ Jereme M. Sylvain, as Attorney-in-Fact for Glenn S. Boehnlein
Signature date: 10 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DXCM transaction

Common Stock

Award

Transaction value
Shares: +5,841
Change %
Price: $0.000000^*
Shares after: 5,841
Date: 10 Sep 2026
Ownership: Direct
Footnotes: F1

DXCM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 42
Date: 10 Sep 2026
Ownership: By Trust
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

Footnote F2

Shares are held by the Boehnlein 2017 Trust, with respect to which the Reporting Person and the Reporting Person's spouse are co-trustees.